Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease

sanofi
This comes after flops and pullouts from its fellow pharmas.

In Sanofi’s third-quarter results posted early this morning, the French Big Pharma says it is canning a phase 2 trial in idiopathic pulmonary fibrosis (IPF), following poor results from Roche and AstraZeneca.

Buried amid its financials, Sanofi revealed simply that it has “decided to stop the development of SAR156597 in idiopathic pulmonary fibrosis,” which had been in phase 2.

The drug had seen the study completed and top-line data were expected to be known in mid-August, according to clinicaltrials.gov. The primary endpoint had been absolute change from baseline in percent predicted forced vital capacity at one year.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The bispecific IL-4/IL-13 antibody appears to have followed Roche and its failed attempt with its IL-13 drug lebrikizumab in asthma, which it discontinued after mixed results.

RELATED: Double disappointment for AstraZeneca lung drug tralokinumab

Just this week, AstraZeneca also saw its IL-13 mAb flop in two late-stage tests, STRATOS 2 and TROPOS, when it failed to beat out placebo and decrease the need for steroids, respectively, and came after another failed pivotal trial earlier in the year. AZ had already ditched work for its medication in IPF last year. It appears Sanofi couldn’t make it work either.

But SAR156597 still lives on in an early-stage placebo-controlled study in the autoimmune disease diffuse systemic sclerosis, with Sanofi set to see how it’s working next October.

In systemic sclerosis, the body’s immune system attacks the internal organs and a patient’s skin. This type mostly affects women and usually develops between 30 and 50 years of age.

But despite this cutback, and it stopping work on a Zika vaccine, Sanofi’s R&D bill jumped, with expenses booking a 12.9% CER increase to €1.34 billion ($1.56 billion) in the third quarter.

The boost comes amid increased spending on the development programs in immuno-oncology and diabetes drug sotagliflozin, as well as a “low base for comparison” for the third quarter last year, the pharma said.

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.